Subscribe to RSS
DOI: 10.1055/s-0034-1375964
Severe Ductopenia and Cholestasis from Levofloxacin Drug-Induced Liver Injury: A Case Report and Review
Publication History
Publication Date:
31 May 2014 (online)
![](https://www.thieme-connect.de/media/sld/201402/lookinside/thumbnails/10.1055-s-0034-1375964-1.jpg)
Abstract
A 67-year-old woman with hypertension, hypothyroidism, and glaucoma was referred for jaundice and elevated liver function tests. She was treated for streptococcal endophthalmitis with 2 weeks of intravenous (IV) levofloxacin followed by 2 months of oral levofloxacin. The patient had no prior history of liver disease and denied alcohol intake. Her physical exam was remarkable for jaundice and scleral icterus without any stigmata of liver disease. Viral hepatitis serologies and antibodies, including myeloperoxidase, proteinase 3, and antinuclear, antimitochondrial, antiliver kidney microsome, antismooth muscle antibodies, were all within normal limits. The liver biopsy revealed severe cholestasis, extensive bile duct loss, and fibrosis. The patient had no known exposure to any other systemic medications or inciting factors other than levofloxacin. Although there are a few reported cases of drug-induced liver disease (DILI) related to levofloxacin, this case is believed to be the first reported case of ductopenia or vanishing bile duct syndrome (VBDS) associated with levofloxacin. Although fluoroquinolones, such as levofloxacin, are generally considered safe antibiotics, health practitioners must be aware of their association with DILI, as the diagnosis of DILI is one of exclusion and requires a high index of suspicion.
-
References
- 1 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11 (2) 272-276
- 2 Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012; 18 (3) 249-257
- 3 Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol 2007; 102 (3) 558-562 , quiz 693
- 4 Reuben A, Koch DG, Lee WM ; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52 (6) 2065-2076
- 5 Reuben A. Hy's law. Hepatology 2004; 39 (2) 574-578
- 6 Zimmerman H. Hepatotoxicity - The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia: Lippincott, Williams & Wilkins; 1999. :606, 616–618
- 7 Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22 (2) 145-155
- 8 Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 2011; 7 (7) 875-890
- 9 Bleibel W, Kim S, D'Silva K, Lemmer ER. Drug-induced liver injury: review article. Dig Dis Sci 2007; 52 (10) 2463-2471
- 10 Rockey DC, Seeff LB, Rochon J , et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51 (6) 2117-2126
- 11 Andrade RJ, Lucena MI, Fernández MC , et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129 (2) 512-521
- 12 Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44 (5) 731-735
- 13 Fontana RJ, Seeff LB, Andrade RJ , et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52 (2) 730-742
- 14 Ostapowicz G, Fontana RJ, Schiødt FV , et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137 (12) 947-954
- 15 Orman ES, Conjeevaram HS, Vuppalanchi R , et al; DILIN Research Group. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9 (6) 517-523 , e3
- 16 Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005; 118 (3) 259-268
- 17 Licata A, Randazzo C, Morreale I, Butera G, D'Alessandro N, Craxì A. Fluoroquinolone-induced liver injury: three new cases and a review of the literature. Eur J Clin Pharmacol 2012; 68 (5) 525-532
- 18 Questions and Answers on Trovafloxacin Public Health Advisory U.S. Food and Drug administration website. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053104.htm . Accessed September 28, 2013
- 19 Karim A, Ahmed S, Rossoff LJ, Siddiqui RK, Steinberg HN. Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis 2001; 33 (12) 2088-2090
- 20 Spahr L, Rubbia-Brandt L, Marinescu O, Armenian B, Hadengue A. Acute fatal hepatitis related to levofloxacin. [letter] J Hepatol 2001; 35 (2) 308-309
- 21 Robinson W, Habr F, Manlolo J, Bhattacharya B. Moxifloxacin associated vanishing bile duct syndrome. [letter] J Clin Gastroenterol 2010; 44 (1) 72-73
- 22 Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997; 26 (Suppl. 01) 31-35
- 23 Levy C, Lindor KD. Drug-induced cholestasis. Clin Liver Dis 2003; 7 (2) 311-330
- 24 Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis 2008; 12 (1) 203-217 , x
- 25 Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol 2002; 37 (5) 696-699